Numrah Fadra

CONFLICT OF INTEREST STATEMENT Daniel Ahn reports consulting fees from Advanced Accelerator Applications, Bayer HealthCare Pharmaceuticals Inc, Daiichi Sankyo, Eisai Inc, Exelixis, Genentech USA, Incyte Corporation, Ipsen Biopharmaceuticals, and Novartis; and stock with Eli Lilly and Company and Natera.

Tyler Shugg1†, Reynold C. Ly2†, Wilberforce Osei1, Elizabeth J. Rowe1, Caitlin A. Granfield2, Ty C. Lynnes2, Elizabeth B. Medeiros2, Jennelle C. Hodge2, Amy M. Breman2, Bryan P. Schneider3, S. Cenk Sahinalp4, Ibrahim Numanagić5, Benjamin A. Salisbury6, Steven M. Bray6, Ryan Ratcliff6 and Todd C.

RNA expression profiling We identified EWSR1::FLI1 fusion transcripts with retained EWSR1 exon 8 in both ALES cases (Figure 4B,C). All four BST ES cases had a EWSR1::FLI1 fusion transcript with break points between EWSR1 exon 7 and FLI1 exon 6, as determined by RNA sequencing (Figure ). We also found that splicing regulators of the pre-mRNA of EWSR1::FLI1 fusion transcript HNRNPH1,13 SUPT6H, and SF3B114 were overexpressed in all ALES and BST ES cases.